Abstracts tagged "Raynaud’s"

Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
Abstract Number: 0700 • ACR Convergence 2024
Prospective Evaluation of Capillaroscopy in Healthy Children
Tessa Dufour¹, Maurizio Cutolo², Dieneke Schonenberg-Meinema³, Kaat Wyckstandt⁴, Adela Sarbu⁵, joke dehoorne⁶, Steven Wallaert⁷ and vanessa smith⁸, ¹University Hospital Ghent, Gent, Belgium, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genova, Italy, ³Amsterdam University Medical Center, Amsterdam, Netherlands, ⁴University Hospital Ghent, Ghent, Belgium, ⁵University hospital Bern, Bern, Switzerland, ⁶University Hospital Ghent, Ghent, ⁷Ghent University, Ghent, Belgium, ⁸Ghent University Hospital, Gent, Belgium
Background/Purpose: Capillaroscopy is a well-established tool in the diagnosis of adult-onset rheumatic diseases and global consensus on standardisation of execution and interpretation performing capillaroscopy have…
Abstract Number: 0702 • ACR Convergence 2024
AISA 021, a Novel Calcium Channel Antagonist in Development for Raynaud’s & Systemic Sclerosis, Has Antagonistic Activity at Sodium Channel Targets for Pain Relief and Treats Scleroderma Pain Better Than Current Calcium Channel Blockers in a Phase 2A Study
Andrew Sternlicht¹ and Meredith Todd², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia
Background/Purpose: Improved treatments for Raynaud's phenomenon in Systemic Sclerosis (SSc) are needed. A novel oral calcium channel blocker (cilnidipine), with N-type channel antagonism is being…
Abstract Number: PP11 • ACR Convergence 2024
Living Well with Chronic Illness: Decades with MCTD
Carol KAMINSKI, HP (Hewlett Packard) Retired, Wilmington, NC
Background/Purpose: In the fall of 1985, I was not feeling well. I attributed my tiredness, weakness and malaise to stress and carried on. Walking upstairs I…
Abstract Number: 0625 • ACR Convergence 2023
Use of Heated Gloves for Raynaud’s Phenomenon in Systemic Sclerosis
Kimti Kumar¹, Nor Hashimah Abu Mansor Matardiah², Kim Griggs³, Aline Kunnel⁴, Jennifer Walker⁵ and Susanna Proudman⁶, ¹SA Health and University of Adelaide, Millswood, Australia, ²Tuanku Fauziah Hospital, Kangar, Malaysia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴South Australian Health and Medical Research Institute, Adelaide, Australia, ⁵Flinders Medical Centre and Royal Adelaide Hospital, Bedford Park, Australia, ⁶Royal Adelaide Hospital and University of Adelaide, Adelaide, Australia
Background/Purpose: RP and its ischaemic complications are a major cause of morbidity in SSc. Non-pharmacological measures to minimise cold exposure can play a vital role…
Abstract Number: 1225 • ACR Convergence 2023
Nailfold Video Capillaroscopy and Its Association with Autoantibodies and Rheumatic Diseases in Pediatric Patients
Yazmin Espinosa¹, Sara Concha¹, Clara Schulze¹ and Antonia Valenzuela², ¹Pontificia Universidad Católica de Chile, Santiago de Chile, Chile, ²Pontificia Universidad Católica de Chile, Santiago, Chile
Background/Purpose: Nailfold video capillaroscopy (NVC) is useful in diagnosing secondary Raynaud's phenomenon (RP) and predicting systemic sclerosis (SSc) and other CTD in adults. Recent studies…
Abstract Number: 1930 • ACR Convergence 2023
Blue Digit Syndrome as the Initial Presentation of Various Diseases: A Case Series
Raquel Ugena García¹, Juan José Lluch Galcerá², Cristina Calomarde Gomez¹, Ivette Casafont-Sole³ and Lourdes Mateo Soria², ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Germans Trias i Pujol, Badalona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain
Background/Purpose: Blue Digit Syndrome (BDS) represents the cutaneous manifestation of numerous diseases that cause blue discoloration in one or more fingers in the absence of…
Abstract Number: 1541 • ACR Convergence 2022
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
Michael Hughes¹, Stefano Di Donato², Klodian Gjeloshi³, Giuseppina Abignano⁴, Fiammetta Danzo³, Giovanni Lettieri G⁴, Enrico De Lorenzis², Dominic Bertham⁵, Philip O’Connor², Olga Kubassova⁶ and Francesco Del Galdo², ¹Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ³University of Campania ‘‘Luigi Vanvitelli’’, Napoli, Italy, ⁴Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Image Analysis Group, London, United Kingdom
Background/Purpose: Fibroproliferative vasculopathy in systemic sclerosis (SSc) is caused by neointima proliferation is a key pathologic feature of SSc which results in arterial vessel narrowing…
Abstract Number: 1773 • ACR Convergence 2022
Epidemiology and Outcomes of Raynaud’s Phenomenon Hospitalizations in the US
Rashmi Dhital¹, Monica Guma², Thuthiri Lwin³, Amar Suwal⁴ and Brian Pedersen¹, ¹UC San Diego, San Diego, CA, ²UCSD, La Jolla, CA, ³University of California San Diego, San Diego, CA, ⁴Reading Hospital, Tower Health, Reading, PA
Background/Purpose: The prevalence of Raynaud's phenomenon (RP) in the general population is ~3-5%, of which 80–90% are primary. Autoimmune diseases are the most common causes…
Abstract Number: 1518 • ACR Convergence 2022
Prevalence, Risk Factors and Treatment Patterns of Digital Ischemic Complications in Systemic Sclerosis: A Single Center Cross-Sectional Study
Ashima Makol¹, Alicia Hinze², Rachel Giblon¹, Yasser Radwan³, Tina Gunderson⁴, David Liedl¹, Kenneth J. Warrington⁴, Cynthia Crowson⁵ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, Rochester, MN, ²Mayo Clinic - Rochester, MN, Rochester, MN, ³Mayo Clinic/ Michigan State University, Lansing, MI, ⁴Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Digital ischemic complications (DICs, including digital ulcers, digital pitting/scars, gangrene and/or amputation) can significantly impact hand function, disability and overall prognosis in SSc. We…
Abstract Number: 0412 • ACR Convergence 2021
Prevalence, Distribution, Clinical Correlates and Outcomes of Upper Extremity Macrovascular Disease in Systemic Sclerosis: Results from a Single Center Referral Cohort (2001-2018)
Ashima Makol¹, Caitrin Coffey¹, Tina Gunderson¹, Alicia Hinze¹, Yasser Radwan², Cynthia Crowson³, David Liedl¹, Kenneth Warrington¹ and Paul Wennberg¹, ¹Mayo Clinic, Rochester, MN, ²Michigan State University, Lansing, MI, ³Mayo Clinic, Eyota, MN
Background/Purpose: To study the prevalence, anatomical distribution, clinical correlates and outcomes of macrovascular disease (MVD) on duplex ultrasound (US) of the upper extremity in Systemic…
Abstract Number: 0923 • ACR Convergence 2020
Criteria for the Diagnosis of Raynaud’s Phenomenon – Do They Recognize the Same Patients?
Martina Plešivčnik-Novljan¹, Daša Šuput Skvarča¹, Ajda Jezernik¹, Saša Čučnik¹, Žiga Rotar¹ and Alojzija Hocevar², ¹University Medical Center Ljubljana, Ljubljana, Ljubljana, Slovenia, ²University Medical Center, Rheumatology, Ljubljana, LJUBLJANA, Slovenia
Background/Purpose: Different criteria aiding the diagnosis of Raynaud’s phenomenon (RP) have been proposed. Wigley’s “RP criteria 2002”, defined RP by history of cold sensitivity, accompanied…
Abstract Number: 1377 • ACR Convergence 2020
Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Tracy Frech¹, Maureen Murtaugh¹, Megan Amuan² and Mary Jo Pugh¹, ¹University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ²Veterans Affair Medical Center, Salt Lake City, UT
Background/Purpose: The purpose of this project was to describe Raynaud's phenomenon (RP), very early diagnosis of systemic sclerosis (VEDOSS), and systemic sclerosis (SSc) in Veterans…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].